已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis

医学 肥胖 2型糖尿病 内科学 自杀意念 保证 儿科 梅德林 糖尿病 青少年肥胖 临床试验 体力活动
作者
Pareeta Kotecha,Wenxi Huang,Ya-Yun Yeh,Valerie Martino Narvaez,Darlene Adirika,Huilin Tang,Angelina Valladares Bernier,SARAH C. WESTEN,Steven M. Smith,Jiang Bian,Jingchuan Serena Guo
出处
期刊:Archives of pediatrics & adolescent medicine [American Medical Association]
卷期号:179 (12): 1308-1308 被引量:58
标识
DOI:10.1001/jamapediatrics.2025.3243
摘要

Importance: Obesity affects 1 in 5 children and adolescents, increasing the risk of type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are among the few pharmacotherapy options available for this population, necessitating a comprehensive evaluation of efficacy and safety. Objective: To assess the efficacy and safety of GLP-1 RAs in children and adolescents (<18 years) with obesity, prediabetes, or T2D. Data Sources: A systematic search was conducted in PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) for randomized clinical trials (RCTs) published from inception until February 28, 2025. Data analysis was completed from January 2025 to April 2025. Study Selection: RCTs comparing GLP-1 RAs to placebo in children and adolescents with obesity, overweight, prediabetes, or T2D with reported safety and efficacy data were included. Data Extraction and Synthesis: Two reviewers independently extracted data on sample size, population, interventions, follow-up, and outcomes. Risk of bias was assessed using version 2 of the Cochrane risk of bias tool (RoB2). Efficacy outcomes (except lipids) were analyzed as estimated treatment differences, lipids as estimated treatment ratios, and safety via rate ratios. A random-effects inverse variance model was used for all outcomes. Main Outcomes and Measures: The primary efficacy outcomes were change in hemoglobin A1c (HbA1c) (in percentage points), fasting glucose (in milligrams per deciliter), body weight (in kilograms), body mass index (BMI, calculated as weight in kilograms divided by height in meters squared), BMI z scores or percentiles, BMI standard deviation score (SDS), lipid outcomes, and blood pressure. Exploratory efficacy outcomes included obstructive sleep apnea and metabolic dysfunction-associated steatohepatitis or metabolic dysfunction-associated steatotic liver disease. Safety outcomes included gastrointestinal adverse effects (GI AEs), infections, hepatobiliary disorders, suicidal ideation or behaviors, depression, hypoglycemia, and adverse event discontinuations. Results: A total of 18 RCTs (11 in obesity, 6 in T2D, and 1 in prediabetes) with 1402 participants (838 GLP-1 RA users and 564 placebo) were included (mean [range] age, 13.7 [6-17] years; 831 female participants (59.3%); median [IQR] treatment duration, 0.51 [0.25-1.00] years). GLP-1 RAs significantly reduced HbA1c (-0.44%; 95% CI, -0.68% to -0.21%), fasting glucose (-9.92 mg/dL; 95% CI, -16.20 to -3.64), body weight (-3.02 kg; 95% CI, -4.98 to -1.06), BMI (-1.45; 95% CI, -2.40 to -0.49), BMI SDS (-0.20; 95% CI, -0.36 to -0.05), BMI percentile (-7.24%; 95% CI, -12.97% to -1.51%), and systolic blood pressure (-2.73 mm Hg; 95% CI, -4.04 to -1.43) and increased GI AE (log[rate ratio] [RR], 0.75). Other AEs, including suicidal ideation or behaviors, showed no significant differences. Conclusions and Relevance: In this systematic review and meta-analysis of 18 trials, GLP-1 RAs significantly improved glycemic, weight, and cardiometabolic outcomes in children and adolescents with T2D or obesity. Available data over a relatively short follow-up suggested suicidal ideation or behaviors were not significantly different, although GI AEs warrant attention in long-term management.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
认真的诗槐完成签到 ,获得积分10
1秒前
气球好饿发布了新的文献求助10
2秒前
和谐的亦丝完成签到,获得积分10
2秒前
在水一方的应助被五味子采纳,获得10
3秒前
3秒前
geejee完成签到,获得积分10
4秒前
踏实乐枫发布了新的文献求助10
4秒前
LuciusHe完成签到,获得积分10
6秒前
jettka完成签到,获得积分10
6秒前
背后的怜珊完成签到 ,获得积分10
7秒前
不倒立完成签到 ,获得积分20
8秒前
花花发布了新的文献求助10
8秒前
诚朴勤仁完成签到,获得积分10
11秒前
风趣的紫霜关注了科研通微信公众号
11秒前
我要看文献完成签到 ,获得积分10
11秒前
Enigma完成签到,获得积分10
12秒前
在地上等馅饼完成签到,获得积分10
12秒前
Maestro_S的应助被DW采纳,获得100
12秒前
TT完成签到,获得积分10
12秒前
失眠鹤完成签到 ,获得积分10
12秒前
大模型的应助被踏实乐枫采纳,获得10
13秒前
刘旦生完成签到,获得积分10
13秒前
lxyyyds完成签到,获得积分10
13秒前
zizizizi完成签到 ,获得积分20
13秒前
华无剑的应助被dake采纳,获得10
13秒前
14秒前
wesley完成签到 ,获得积分10
16秒前
王化省完成签到,获得积分10
19秒前
彭于晏的应助被气球好饿采纳,获得10
20秒前
24秒前
Milton_z完成签到 ,获得积分0
25秒前
学霸业的应助被DW采纳,获得10
25秒前
华仔的应助被微山采纳,获得10
25秒前
26秒前
27秒前
cjg完成签到 ,获得积分10
28秒前
Rebirth发布了新的文献求助10
28秒前
meow完成签到 ,获得积分10
29秒前
机智的如曼完成签到,获得积分10
29秒前
哦哦哟完成签到 ,获得积分10
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184764
求助须知:如何正确求助?哪些是违规求助? 9573733
关于积分的说明 21832921
捐赠科研通 7782115
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558528
邀请新用户注册赠送积分活动 2481067